**Project Description**

|  |  |
| --- | --- |
| Name  | 2017 Minister-level Seminar on Pharmaceutical Supervision and Management for Developing Countries. |
| Organizer  | Shanghai Fosun Pharmaceutical Development Co., Ltd |
| Time | July.12 —July.18, 2017  | Language | English |
| Invited Countries | Minister-levelofficials in the field of supervision and management of pharmaceutical products for developing countries. |
| Number of Participants | 20  |
| Requirements for the Participants | Age | Minister can bring a director general or a division director as his/her assistant. Under 45 for officials at or under director’s level; under 50 for officials at director general’s level |
| Health | In good health with health certificate issued by the local public hospitals; without diseases with which entry to China is disallowed by China’s laws and regulations; without severe chronic diseases such as serious high blood pressure, cardiovascular/cerebro vascular diseases and diabetes; without metal diseases or epidemic diseases that are likely to cause serious threat to public health; not in the process of recovering after a major operation or in the process of acute diseases; not seriously disabled or pregnant. |
| Language | Capable of listening, speaking, reading and writing in English. |
| others | The expenses of family members or friends coming to and staying in China will be not covered by the Chinese Governmen.   |
| Host City | Beijing | Local temperature  | 19-30℃ |
| Cities to visit | Shanghai | Local temperature | 21-27℃ |
| Notes |  |
| Contact of the organizer | Contact Person | Miss Huang Ling ；Mr Su Mingjie |
| Phone | 0086-10-59770902 |
| Mobile phone | 0086-13811119236( Huang Ling )，0086-13564353804( Su Mingjie ) |
| Fax | 0086-10-59770955 |
| E-mail |  huangl@guilinpharma.com ( Huang Ling )；sumj@ guilinpharma.com ( Su Mingjie );  |
| About the Organizer  | Shanghai Fosun Pharmaceutical Development Co., Ltd. is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. specialized in medical R&D, manufacturing and sales. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“FosunPharma”), a leading healthcare company in China，which was established in 1994 ,has been listed on Shanghai Stock Exchange since August 1998 and on the Main Board of the Stock Exchange of Hong Kong Limited.Specializing in modern biopharmaceutical and healthcare industry, FosunPharma has captured opportunities within the rapidly developing Chinese healthcare industry as well as from the globalization of Chinese healthcare companies in general. FosunPharma's operations strategically cover several important segments of the healthcare industry value-chain, including: pharmaceutical manufacturing, distribution and retail. In particular, the Company has a leading market position and unmatched advantages in pharmaceutical distribution and retail, healthcare services, diagnostic products and medical devices, and maintains a strong focus on research and development, and manufacturing. As one of the largest healthcare companies in China, FosunPharma enjoys a competitive advantage in research and development, innovation, marketing, integration of mergers and acquisitions, as well as human resources.As a result of its focus on innovation, research and development, Shanghai Fosun Pharmaceutical Development Co., Ltd.maintains a highly capable international R&D team with operations in Shanghai and Chongqing and United States in addition to its National Recognized Enterprise Technology Centre. FosunPharma's research and development activities cover therapeutic areas such as metabolism and alimentary tract, the cardiovascular system, anti-tumor,central nervous system and anti-infective drug. FosunPharmais the global leader in anti-malaria, and has a competitive advantage in theliver diseases, diabetes, tuberculosis and diagnostic product in China. |
| Seminar Content | Shanghai Fosun Pharmaceutical Development Co., Ltd. will organize “2017 Minister-level Seminar on Pharmaceutical Supervision and Management for Developing Countries” in China. It is authorized by Ministry of Commerce of the People’s Republic of China (MOFCOM). The seminar will be held on July 12 to July 18, for 7 days. The Seminar includes lectures, discussion and onsite visiting. We will invite Chinese experts and government officials to introduce such as drug registration and post-marketing surveillance, drug inspection system and quality standard, traditional medicine development and trend, adverse drug reaction monitoring and rational drug use, Chinese drug fast inspection technology, etc. Meanwhile, we will arrange the participants to visit Shanghai to fully understand the development trend of China's drug regulatory, ascending consensus, promote cooperation. |